Italy amends marketing permission for eribulin medicine Eribulina Glenmark
Italy's medicines agency AIFA has published an official notice in the Gazzetta Ufficiale dated 31 October 2026 about a change to the marketing authorization for 'Eribulina Glenmark', a human medicine containing eribulin. A marketing authorization is the official permission that lets a medicine be sold. The excerpt does not say what the change is.
This summary was generated by AI; the official source prevails.
What does it mean?
Italy's medicines regulator has officially changed the sales permission for Eribulina Glenmark, a medicine that contains eribulin. The notice does not explain the change, so the exact effect for patients and pharmacies is not clear from this excerpt.
Who is affected?
Patients who use Eribulina Glenmark, and the pharmacies and companies that supply it in Italy.